Abstract
Aims: To examine the course and the predictors of the persistence of cannabis dependence. Methods: Through cannabis outlets and chain referral, a prospective enriched community cohort of 207 young adults (aged 18-30) with DSM-IV cannabis dependence at baseline (T0) was formed and followed-up after 1.5 (T1) and 3 (T2) years. The presence of cannabis dependence, cannabis-related problems, functional impairment and treatment was assessed using the Composite International Diagnostic Interview (CIDI 3.0) and the Sheehan Disability Scale (SDS). Predictors of persistence were lifetime cannabis abuse and dependence symptoms, cannabis use characteristics, distant vulnerability factors (e.g. childhood adversity, family history of psychological/substance use problems, impulsivity, mental disorders), and proximal stress factors (recent life events, social support). Results: Four groups were distinguished: persistent dependent (DDD: 28.0%), stable non-persistent (DNN: 40.6%), late non-persistent (DDN: 17.9%) and recurrent dependent (DND: 13.5%). At T2, persisters (DDD) reported significantly more (heavy) cannabis use and cannabis problems than non-persisters (DNN/DDN/DND). Treatment seeking for cannabis-related problems was rare, even among persisters (15.5%). The number (OR = 1.23 (1.03-1.48)) and type (‘role impairment' OR = 2.85 (1.11-7.31), ‘use despite problems' OR = 2.34 (1.15-4.76)) of lifetime cannabis abuse/dependence symptoms were the only independent predictors of persistence with a total explained variance of 8.8%. Conclusions: Persistence of cannabis dependence in the community is low, difficult to predict, and associated with a negative outcome. The substantial proportion of stable non-persisters suggests that screening and monitoring or low-threshold brief interventions may suffice for many non-treatment-seeking cannabis-dependent people. However, those with many lifetime abuse/dependence symptoms may benefit from more intensive interventions.
Journal Section:
Editor's choice
References
1.
Conway KP, Compton W, Stinson FS, Grant BF: Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2006;67:247-257.
[PubMed]
2.
Stinson FS, Ruan WJ, Pickering R, Grant BF: Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med 2006;36:1447-1460.
[PubMed]
3.
UNODC: World Drug Report: 2010. Vienna, UNODC, 2010.
4.
Degenhardt L, Hall W: Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012;379:55-70.
[PubMed]
5.
Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J, Flaxman AD, Engell RE, Freedman GD, Whiteford HA, Vos T: The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One 2013;8:e76635.
[PubMed]
6.
Newcomb MD, Galaif ER, Locke TF: Substance use diagnoses within a community sample of adults: distinction, comorbidity, and progression over-time. Prof Psychol Res Pract 2001;32:239-247.
7.
Perkonigg A, Goodwin RD, Fiedler A, Behrendt S, Beesdo K, Lieb R, Wittchen HU: The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction 2008;103:439-449; discussion 450-451.
[PubMed]
8.
Calabria B, Degenhardt L, Briegleb C, Vos T, Hall W, Lynskey M, Callaghan B, Rana U, McLaren J: Systematic review of prospective studies investigating ‘remission' from amphetamine, cannabis, cocaine or opioid dependence. Addict Behav 2010;35:741-749.
[PubMed]
9.
Denis C, Lavie E, Fatseas M, Auriacombe M: Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database Syst Rev 2006;3:CD005336.
[PubMed]
10.
Danovitch I, Gorelick DA: State of the art treatments for cannabis dependence. Psychiatr Clin North Am 2012;35:309-326.
[PubMed]
11.
Flórez-Salamanca L, Secades-Villa R, Budney AJ, Garcia-Rodriguez O, Wang S, Blanco C: Probability and predictors of cannabis use disorders relapse: results of the national epidemiologic survey on alcohol and related conditions (NESARC). Drug Alcohol Depend 2013;132:127-133.
[PubMed]
12.
Rubio JM, Olfson M, Villegas L, Perez-Fuentes G, Wang S, Blanco C: Quality of life following remission of mental disorders: findings from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2013;74:e445-e450.
[PubMed]
13.
Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jorgensen P: Psychopathology among cannabis-dependent treatment seekers and association with later substance abuse treatment. J Subst Abuse Treat 2007;32:113-119.
[PubMed]
14.
Chen KW, Banducci AN, Guller L, Macatee RJ, Lavelle A, Daughters SB, Lejuez CW: An examination of psychiatric comorbidities as a function of gender and substance type within an inpatient substance use treatment program. Drug Alcohol Depend 2011;118:92-99.
[PubMed]
15.
Van der Pol P, Liebregts N, de Graaf R, Korf DJ, Van den Brink W, van Laar M: Facilitators and barriers in treatment seeking for cannabis dependence. Drug Alcohol Depend 2013;133:776-780.
[PubMed]
16.
Grella CE, Stein JA: Remission from substance dependence: differences between individuals in a general population longitudinal survey who do and do not seek help. Drug Alcohol Depend 2013;133:146-153.
[PubMed]
17.
Swift W, Hall W, Copeland J: One year follow-up of cannabis dependence among long-term users in Sydney, Australia. Drug Alcohol Depend 2000;59:309-318.
[PubMed]
18.
van der Pol P, Liebregts N, De Graaf R, Korf DJ, van den Brink W, van Laar M: Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. Drug Alcohol Depend 2013;133:352-359.
[PubMed]
19.
de Bruijn C, van den Brink W, de Graaf R, Vollebergh WA: Alcohol abuse and dependence criteria as predictors of a chronic course of alcohol use disorders in the general population. Alcohol 2005;40:441-446.
[PubMed]
20.
Gilder DA, Lau P, Corey L, Ehlers CL: Factors associated with remission from cannabis dependence in southwest California Indians. J Addict Dis 2007;26:23-30.
[PubMed]
21.
Lopez-Quintero C, Hasin DS, de Los Cobos JP, Pines A, Wang S, Grant BF, Blanco C: Probability and predictors of remission from life-time nicotine, alcohol, cannabis or cocaine dependence: results from the national epidemiologic survey on alcohol and related conditions. Addiction 2011;106:657-669.
[PubMed]
22.
Temple EC, Brown RF, Hine DW: The ‘grass ceiling': limitations in the literature hinder our understanding of cannabis use and its consequences. Addiction 2011;106:238-244.
[PubMed]
23.
Johnson K, Mullin JL, Marshall EC, Bonn-Miller MO, Zvolensky M: Exploring the mediational role of coping motives for marijuana use in terms of the relation between anxiety sensitivity and marijuana dependence. Am J Addict 2010;19:277-282.
[PubMed]
24.
Hides L, Lubman DI, Cosgrave EM, Buckby JA, Killackey E, Yung AR: Motives for substance use among young people seeking mental health treatment. Early Interv Psychiatry 2008;2:188-194.
[PubMed]
25.
Bujarski SJ, Norberg MM, Copeland J: The association between distress tolerance and cannabis use-related problems: the mediating and moderating roles of coping motives and gender. Addict Behav 2012;37:1181-1184.
[PubMed]
26.
Agosti V, Nunes E, Levin F: Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse 2002;28:643-652.
[PubMed]
27.
Lopez-Quintero C, Cobos JP, Hasin DS, Okuda M, Wang S, Grant BF, Blanco C: Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the national epidemiologic survey on alcohol and related conditions (NESARC). Drug Alcohol Depend 2011;115:120-130.
[PubMed]
28.
von Sydow K, Lieb R, Pfister H, Hofler M, Sonntag H, Wittchen HU: The natural course of cannabis use, abuse and dependence over four years: a longitudinal community study of adolescents and young adults. Drug Alcohol Depend 2001;64:347-361.
[PubMed]
29.
Wittchen HU, Frohlich C, Behrendt S, Gunther A, Rehm J, Zimmermann P, Lieb R, Perkonigg A: Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. Drug Alcohol Depend 2007;88(suppl 1):S60-S70.
[PubMed]
30.
Buckner JD, Schmidt NB, Lang AR, Small JW, Schlauch RC, Lewinsohn PM: Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. J Psychiatr Res 2008;42:230-239.
[PubMed]
31.
Harris T: Where Inner and Outer Worlds Meet: Psychosocial Research in the Tradition of George W Brown. London, Routledge, 2000.
32.
Bruns C, Geist CS: Stressful life events and drug use among adolescents. J Human Stress 1984;10:135-139.
[PubMed]
33.
Hyman SM, Sinha R: Stress-related factors in cannabis use and misuse: implications for prevention and treatment. J Subst Abuse Treat 2009;36:400-413.
[PubMed]
34.
Windle M, Wiesner M: Trajectories of marijuana use from adolescence to young adulthood: predictors and outcomes. Dev Psychopathol 2004;16:1007-1027.
[PubMed]
35.
van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M: The Dutch cannabis dependence (CanDep) study on the course of frequent cannabis use and dependence: objectives, methods and sample characteristics. Int J Methods Psychiatr Res 2011;20:169-181.
[PubMed]
36.
Kessler RC, Ustun TB: The world mental health (WMH) survey initiative version of the world health organization (WHO) composite international diagnostic interview (CIDI). Int J Methods Psychiatr Res 2004;13:93-121.
[PubMed]
37.
Sheehan DV: The Anxiety Disease. New York, Scribner, 1983.
38.
Ware JE, Snow KK, Kosinski M, Gandek B: Health Survey Manual and Interpretation Guide. Boston, Health Institute, New England Medical Centre, 1993.
39.
Von Korff M, Crane PK, Alonso J, Vilagut G, Angermeyer MC, Bruffaerts R, de Girolamo G, Gureje O, de Graaf R, Huang Y, Iwata N, Karam EG, Kovess V, Lara C, Levinson D, Posada-Villa J, Scott KM, Ormel J: Modified WHODAS-II provides valid measure of global disability but filter items increased skewness. J Clin Epidemiol 2008;61:1132-1143.
[PubMed]
40.
van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M: Validation of self-reported cannabis dose and potency: an ecological study. Addiction 2013;108:1801-1808.
[PubMed]
41.
Simons JS, Gaher RM, Correia CJ, Hansen CL, Christopher MS: An affective-motivational model of marijuana and alcohol problems among college students. Psychol Addict Behav 2005;19:326-334.
[PubMed]
42.
Bohn MJ, Babor TF, Kranzler HR: The alcohol use disorders identification test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol 1995;56:423-432.
[PubMed]
43.
Burling AS, Burling TA: A comparison of self-report measures of nicotine dependence among male drug/alcohol-dependent cigarette smokers. Nicotine Tob Res 2003;5:625-633.
[PubMed]
44.
Hovens JG, Wiersma JE, Giltay EJ, van Oppen P, Spinhoven P, Penninx BW, Zitman FG: Childhood life events and childhood trauma in adult patients with depressive, anxiety and comorbid disorders vs. controls. Acta Psychiatr Scand 2010;122:66-74.
[PubMed]
45.
Janssen I, Krabbendam L, Bak M, Hanssen M, Vollebergh W, de Graaf R, van Os J: Childhood abuse as a risk factor for psychotic experiences. Acta Psychiatr Scand 2004;109:38-45.
[PubMed]
46.
Konings M, Stefanis N, Kuepper R, de Graaf R, ten Have M, van Os J, Bakoula C, Henquet C: Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. Psychol Med 2012;42:149-159.
[PubMed]
47.
Zeisser C, Thompson K, Stockwell T, Duff C, Chow C, Vallance K, Ivsins A, Michelow W, Marsh D, Lucas P: A ‘standard joint'? The role of quantity in predicting cannabis-related problems. Addict Res Theory 2011;20:82-92.
48.
van der Pol P, Liebregts N, de Graaf R, Ten Have M, Korf DJ, van den Brink W, van Laar M: Mental health differences between frequent cannabis users with and without cannabis dependence and the general population. Addiction 2013;108:1459-1469.
[PubMed]
49.
Spinella MARC: Normative data and a short form of the Barratt impulsiveness scale. Int J Neurosci 2007;117:359-368.
[PubMed]
50.
Brugha T, Bebbington P, Tennant C, Hurry J: The list of threatening experiences: a subset of 12 life event categories with considerable long-term contextual threat. Psychol Med 1985;15:189-194.
[PubMed]
51.
Hosmer DW, Lemeshow S, Sturdivant RX: Applied Logistic Regression, ed 3. Wiley, 2013, p 95.
52.
Bonn-Miller MO, Zvolensky MJ: An evaluation of the nature of marijuana use and its motives among young adult active users. Am J Addict 2009;18:409-416.
[PubMed]
53.
Chabrol H, Duconge E, Casas C, Roura C, Carey KB: Relations between cannabis use and dependence, motives for cannabis use and anxious, depressive and borderline symptomatology. Addict Behav 2005;30:829-840.
[PubMed]
54.
Fox CL, Towe SL, Stephens RS, Walker DD, Roffman RA: Motives for cannabis use in high-risk adolescent users. Psychol Addict Behav 2011;25:492-500.
[PubMed]
55.
Johnson K, Mullin JL, Marshall EC, Bonn-Miller MO, Zvolensky M: Exploring the mediational role of coping motives for marijuana use in terms of the relation between anxiety sensitivity and marijuana dependence. Am J Addict 2010;19:277-282.
[PubMed]
56.
Gates P, Copeland J, Swift W, Martin G: Barriers and facilitators to cannabis treatment. Drug Alcohol Rev 2012;31:311-319.
[PubMed]
57.
Agrawal A, Lynskey MT, Bucholz KK, Kapoor M, Almasy L, Dick DM, et al: DSM-5 cannabis use disorder: a phenotypic and genomic perspective. Drug Alcohol Depend 2014;134:362-369.
[PubMed]
58.
Agrawal A, Lynskey MT: The genetic epidemiology of cannabis use, abuse and dependence. Addiction 2006;101:801-812.
[PubMed]
59.
Lynskey MT, Heath AC, Nelson EC, Bucholz KK, Madden PAF, Slutske WS, et al: Genetic and environmental contributions to cannabis dependence in a national young adult twin sample. Psychol Med 2002;32:195-207.
[PubMed]
60.
Cousijn J, Goudriaan AE, Ridderinkhof KR, van den Brink W, Veltman DJ, Wiers RW: Neural responses associated with cue-reactivity in frequent cannabis users. Addict Biol 2013;18:570-580.
[PubMed]
61.
Henquet C, van Os J, Kuepper R, Delespaul P, Smits M, Campo JA, Myin-Germeys I: Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry 2010;196:447-453.
[PubMed]
62.
Larson R, Csikszentmihalyi M: The experience sampling method. New Dir Meth Soc Behav Sci 1983;15:41-56.
63.
Liebregts N, van der Pol P, van Laar M, de Graaf R, van den Brink W, Korf DJ: The role of study and work in cannabis use and dependence trajectories among young adult frequent cannabis users. Front Psychiatry 2013;4:85.
[PubMed]
64.
Liebregts N, van der Pol P, van Laar M, de Graaf R, van den Brink W, Korf DJ: The role of leisure and delinquency in frequent cannabis use and dependence trajectories among young adults. Int J Drug Policy 2015:26:143-152.
[PubMed]
65.
Rooke S, Copeland J, Norberg M, Hine D, McCambridge J: Effectiveness of a self-guided web-based cannabis treatment program: randomized controlled trial. J Med Internet Res 2013;15:e26.
[PubMed]
66.
Tait RJ, Spijkerman R, Riper H: Internet and computer based interventions for cannabis use: a meta-analysis. Drug Alcohol Depend 2013;133:295-304.
[PubMed]
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.
